Mycobacterium tuberculosis has afflicted humans for thousands of years and continues to cause an enormous worldwide burden of disease. Despite the availability of effective treatment regimens for the last 40 years, today still more people die from tuberculosis (TB) than any other infection. The goal of the Philips laboratory is to help change the face of the TB epidemic. The world needs shorter treatments and an effective vaccine, but currently we lack a road map to these objectives. We believe that to make transformative steps forward, we will have to understand the molecular pathogenesis of M. tuberculosis. We study how M. tuberculosis is able to undermine the host immune system, surviving in cells that are normally dedicated to killing bacteria. This basic understanding will enable new treatments, allowing us to tip the balance in favor of the host.